vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and UDR, Inc. (UDR). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $433.1M, roughly 1.4× UDR, Inc.). UDR, Inc. runs the higher net margin — 51.5% vs 34.4%, a 17.0% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 2.5%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 2.3%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
UDR, Inc. is a leading U.S.-headquartered real estate investment trust specializing in owning, operating, and redeveloping high-quality multifamily residential apartment communities. It operates across major U.S. metropolitan markets, catering to a diverse tenant base including young professionals, families, and middle-to-high income households.
RPRX vs UDR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $433.1M |
| Net Profit | $214.2M | $222.9M |
| Gross Margin | — | — |
| Operating Margin | 62.4% | 64.1% |
| Net Margin | 34.4% | 51.5% |
| Revenue YoY | 4.8% | 2.5% |
| Net Profit YoY | 2.9% | 4519.2% |
| EPS (diluted) | $0.49 | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $433.1M | ||
| Q3 25 | $609.3M | $431.9M | ||
| Q2 25 | $578.7M | $425.4M | ||
| Q1 25 | $568.2M | $421.9M | ||
| Q4 24 | $593.6M | $422.7M | ||
| Q3 24 | $564.7M | $420.2M | ||
| Q2 24 | $537.3M | $415.3M | ||
| Q1 24 | $568.0M | $413.6M |
| Q4 25 | $214.2M | $222.9M | ||
| Q3 25 | $288.2M | $40.4M | ||
| Q2 25 | $30.2M | $37.7M | ||
| Q1 25 | $238.3M | $76.7M | ||
| Q4 24 | $208.2M | $-5.0M | ||
| Q3 24 | $544.0M | $22.6M | ||
| Q2 24 | $102.0M | $28.9M | ||
| Q1 24 | $4.8M | $43.1M |
| Q4 25 | 62.4% | 64.1% | ||
| Q3 25 | 70.1% | 17.7% | ||
| Q2 25 | 36.3% | 18.2% | ||
| Q1 25 | 94.0% | 29.0% | ||
| Q4 24 | 60.9% | 15.7% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | 50.2% | 16.5% | ||
| Q1 24 | -13.0% | 19.3% |
| Q4 25 | 34.4% | 51.5% | ||
| Q3 25 | 47.3% | 9.4% | ||
| Q2 25 | 5.2% | 8.9% | ||
| Q1 25 | 41.9% | 18.2% | ||
| Q4 24 | 35.1% | -220.5% | ||
| Q3 24 | 96.3% | 5.4% | ||
| Q2 24 | 19.0% | 7.0% | ||
| Q1 24 | 0.8% | 10.4% |
| Q4 25 | $0.49 | $0.67 | ||
| Q3 25 | $0.67 | $0.12 | ||
| Q2 25 | $0.07 | $0.11 | ||
| Q1 25 | $0.55 | $0.23 | ||
| Q4 24 | $0.46 | $-0.01 | ||
| Q3 24 | $1.21 | $0.06 | ||
| Q2 24 | $0.23 | $0.08 | ||
| Q1 24 | $0.01 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $1.2M |
| Total DebtLower is stronger | $9.0B | $5.8B |
| Stockholders' EquityBook value | $9.7B | $3.3B |
| Total Assets | $19.6B | $10.6B |
| Debt / EquityLower = less leverage | 0.92× | 1.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $1.2M | ||
| Q3 25 | $938.9M | $1.2M | ||
| Q2 25 | $631.9M | $1.5M | ||
| Q1 25 | $1.1B | $1.3M | ||
| Q4 24 | $929.0M | $1.3M | ||
| Q3 24 | $950.1M | $2.3M | ||
| Q2 24 | $1.8B | $2.8M | ||
| Q1 24 | $843.0M | $2.1M |
| Q4 25 | $9.0B | $5.8B | ||
| Q3 25 | $8.9B | $5.8B | ||
| Q2 25 | $8.0B | $5.8B | ||
| Q1 25 | $7.6B | $5.8B | ||
| Q4 24 | $7.6B | $5.8B | ||
| Q3 24 | $7.6B | $5.9B | ||
| Q2 24 | $7.6B | $5.8B | ||
| Q1 24 | $6.1B | $5.8B |
| Q4 25 | $9.7B | $3.3B | ||
| Q3 25 | $9.6B | $3.3B | ||
| Q2 25 | $9.5B | $3.3B | ||
| Q1 25 | $9.8B | $3.3B | ||
| Q4 24 | $10.3B | $3.4B | ||
| Q3 24 | $10.3B | $3.5B | ||
| Q2 24 | $9.8B | $3.7B | ||
| Q1 24 | $9.9B | $3.9B |
| Q4 25 | $19.6B | $10.6B | ||
| Q3 25 | $19.3B | $10.6B | ||
| Q2 25 | $18.3B | $10.6B | ||
| Q1 25 | $17.6B | $10.7B | ||
| Q4 24 | $18.2B | $10.9B | ||
| Q3 24 | $18.0B | $11.1B | ||
| Q2 24 | $17.7B | $11.1B | ||
| Q1 24 | $16.1B | $11.2B |
| Q4 25 | 0.92× | 1.77× | ||
| Q3 25 | 0.93× | 1.78× | ||
| Q2 25 | 0.84× | 1.74× | ||
| Q1 25 | 0.78× | 1.74× | ||
| Q4 24 | 0.74× | 1.69× | ||
| Q3 24 | 0.74× | 1.67× | ||
| Q2 24 | 0.78× | 1.55× | ||
| Q1 24 | 0.62× | 1.47× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $902.9M |
| Free Cash FlowOCF − Capex | — | $650.0M |
| FCF MarginFCF / Revenue | — | 150.1% |
| Capex IntensityCapex / Revenue | — | 58.4% |
| Cash ConversionOCF / Net Profit | 3.86× | 4.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $902.9M | ||
| Q3 25 | $702.6M | $234.9M | ||
| Q2 25 | $364.0M | $250.3M | ||
| Q1 25 | $596.1M | $156.2M | ||
| Q4 24 | $742.5M | $876.8M | ||
| Q3 24 | $703.6M | $230.3M | ||
| Q2 24 | $658.2M | $238.5M | ||
| Q1 24 | $664.6M | $167.6M |
| Q4 25 | — | $650.0M | ||
| Q3 25 | — | $164.6M | ||
| Q2 25 | — | $190.1M | ||
| Q1 25 | — | $103.2M | ||
| Q4 24 | — | $627.0M | ||
| Q3 24 | — | $161.3M | ||
| Q2 24 | — | $171.1M | ||
| Q1 24 | — | $115.0M |
| Q4 25 | — | 150.1% | ||
| Q3 25 | — | 38.1% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | 24.5% | ||
| Q4 24 | — | 148.3% | ||
| Q3 24 | — | 38.4% | ||
| Q2 24 | — | 41.2% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | — | 58.4% | ||
| Q3 25 | — | 16.3% | ||
| Q2 25 | — | 14.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 59.1% | ||
| Q3 24 | — | 16.4% | ||
| Q2 24 | — | 16.2% | ||
| Q1 24 | — | 12.7% |
| Q4 25 | 3.86× | 4.05× | ||
| Q3 25 | 2.44× | 5.81× | ||
| Q2 25 | 12.06× | 6.64× | ||
| Q1 25 | 2.50× | 2.04× | ||
| Q4 24 | 3.57× | — | ||
| Q3 24 | 1.29× | 10.19× | ||
| Q2 24 | 6.45× | 8.26× | ||
| Q1 24 | 139.10× | 3.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
UDR
Segment breakdown not available.
